Neoadjuvant atezolizumab has a low rate of significant toxicity or disease progression in patients with advanced cSCC. The high pathological response rate can confer a clinical benefit from reduced ...

These findings have, however, now been questioned by a study that supports the prospect of a tailored surgical approach to rectal-cancer treatment on the basis of tumor behavior after neoadjuvant ...

Findings from the HELEN-006 trial suggest a potential shift in neoadjuvant treatment practices for patients with HER2-positive early breast cancer, specifically using nab-paclitaxel to reduce ...

How neoadjuvant immunotherapy compares with standard adjuvant immunotherapy in patients with resectable, macroscopic stage III melanoma has been unclear. New research findings are summarized in a ...

A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, ...

Is this treatment right for me? Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be ...

The analysis showed an approximate 40% reduction in the risk of disease recurrence or death after surgery among patients who received at least one dose of adjuvant nivolumab following neoadjuvant ...

Combination of radiation, chemotherapy and immunotherapy can shrink tumors and allow surgery, with much better survival rate.

Read on to learn how the impact of chemoradiotherapy for patients receiving neoadjuvant chemoradiotherapy followed by surgery ...

Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...